1. FLIP: Molecular switch between apoptosis and necroptosis
   JingJing Gong et al, 2014, Molecular Carcinogenesis CrossRef
2. The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors
   Daniel E Johnson, 2015, Endocrine-Related Cancer CrossRef
3. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
   G.R. Tundo et al, 2020, Pharmacology & Therapeutics CrossRef
4. MiR-126 reverses drug resistance to TRAIL through inhibiting the expression of c-FLIP in cervical cancer
   Weijiang Zhang et al, 2017, Gene CrossRef
5. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism
   J Bullenkamp et al, 2014, Cell Death & Disease CrossRef
6. Co-expression analysis reveals key gene modules and pathways of oral squamous cell carcinoma
   Xiao Li et al, 2018, Cancer Biomarkers CrossRef
7. Proteasome inhibitor MG132 enhances the sensitivity of human OSCC cells to cisplatin via a ROS/DNA damage/p53 axis
   Zheng Zheng et al, 2023, Experimental and Therapeutic Medicine CrossRef
8. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells
   Eun-Sil Sung et al, 2012, Experimental Cell Research CrossRef
9. TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis
   Syam Prakash Somasekharan et al, 2013, Apoptosis CrossRef
10. Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and New Approaches
    Jason I. Kass et al, 2014, Resistance to Proteasome Inhibitors in Cancer CrossRef